CBD and methotrexate: what I'd want to know as an RA patient who took both
I was on methotrexate earlier in my RA history, before I discovered CBD. I didn't navigate them together directly, so I can't speak from personal experience the way I can about prednisone. What I can tell you is what I researched carefully when building Reclaim, and what I'd want to know if I were in your position today.
The mechanism is real: CBD inhibits CYP3A4, the enzyme that partially clears MTX. That means MTX plasma levels can rise when you add CBD. Bansal 2023 documented CBD raising CYP3A substrate exposure 56–207% at research doses. At wellness CBD doses the magnitude is smaller, but your rheumatologist needs to know so they can keep an eye on your CBC and liver function.
Don't adjust MTX on your own. That's not a legal disclaimer, MTX is a drug with a narrow therapeutic window and the titration belongs with your rheumatologist.
What you need to know
- CBD inhibits CYP3A4, the enzyme that partially clears MTX. This can raise MTX plasma levels, both the therapeutic effect and the side-effect profile can be amplified.
- No MTX-specific CBD trial exists yet, but Bansal 2023 showed the mechanism is clinically real in humans. Treat it as real, not theoretical.
- Your existing CBC and liver function monitoring (standard MTX protocol) is the right safety net, make sure your rheumatologist knows you're adding CBD so they're watching for the right things.
- Format matters: topical CBD has minimal systemic absorption and the lowest CYP impact. If you want to start cautiously, the NANO roll-on is the lowest-risk entry point.
- Start low, titrate slowly. MTX has a narrow therapeutic window, don't add high-dose CBD at the same time you're adjusting MTX.
What the science says
The CYP3A4 pathway evidence
Bansal 2023 is the strongest direct clinical evidence: a randomized, double-blind, placebo-controlled trial in 18 healthy adults found CBD-dominant cannabis raised CYP3A substrate plasma exposure by 56–207%. The mechanism - competitive inhibition of CYP3A4 by CBD - was confirmed in vitro by Yamaori 2011 at clinically achievable concentrations.
The breadth
Stöllberger 2023 reviewed 403 CYP-substrate drugs and concluded CBD has pathway overlap with 67–68% of frequently prescribed medications. Methotrexate is on that list: MTX undergoes CYP3A4-mediated 7-hydroxylation as a minor metabolic pathway alongside its primary UGT glucuronidation and renal elimination.
MTX-specific evidence - the honest gap
There is no MTX-CBD interaction RCT. The closest published parallels are case reports of CBD elevating other autoimmune-relevant immunosuppressants - Cuñetti 2024 documented CBD-induced rises in cyclosporine and mycophenolate plasma levels in a kidney transplant patient. Nachnani 2024's 31-report systematic review similarly catalogs tacrolimus, sirolimus, and warfarin interactions but no MTX-specific case.
What this adds up to
The mechanism is plausible (shared CYP3A4 pathway). The magnitude for MTX specifically isn't quantified. At wellness-CBD doses (25–50mg/day), CYP exposure is lower than in the Bansal trial (~750mg/day equivalent) but not zero. Pharmacogenomic variation matters — different patients have different CYP3A4 activity baselines, so the same dose has different effects in different people.
The mechanism
MTX metabolism is multi-pathway. Roughly 80% of an MTX dose is eliminated unchanged by the kidneys; the remaining ~20% is hepatically processed. Hepatic processing includes CYP3A4-mediated 7-hydroxylation (minor), UGT1A glucuronidation, aldehyde oxidase oxidation, and folate-pathway interaction.
CBD inhibits CYP3A4 competitively — the inhibition is dose-dependent and persists for hours beyond CBD's plasma half-life. CBD also affects UGT1A enzymes, which contribute to MTX glucuronidation; the specific MTX-UGT-CBD interaction has not been quantified clinically.
Because MTX has parallel elimination pathways, partial inhibition of any one shifts the load to the others. The clinical impact depends on which pathway dominates in you - which depends on your kidney function, your folate status, and your CYP3A4 baseline. There is no single magnitude that applies to every patient. See the CYP450 mechanism explainer for the foundational pharmacology.
What this means for you
- Talk to your rheumatologist before starting CBD. Bring this page if helpful. The CYP3A4 + UGT framing helps the conversation move from "I don't know" to specifics.
- Folate monitoring. MTX therapy requires folate supplementation. CBD's effect on the folate pathway hasn't been studied; if you're already on folate, your rheumatologist may want to monitor levels more closely after CBD initiation.
- CBC + LFT monitoring. Standard MTX monitoring (CBC and liver function tests every 8–12 weeks per ACR guidelines) becomes especially important when CBD is added. CBD can elevate liver enzymes at high doses; combined with MTX hepatotoxicity, this is a meaningful flag.
- Format choice. Oral CBD has the highest first-pass through the liver, and therefore the largest CYP impact. Topical CBD (the Reclaim NANO roll-on) has minimal systemic absorption. Transdermal patches (the 50mg patches) deliver CBD systemically but bypass first-pass. If you choose to combine, your rheumatologist may prefer the lower-systemic-exposure format.
- Dose conservatism. If you and your rheumatologist agree to try CBD, start at the low end (10–25mg) and titrate slowly. See our titration protocol for the ramp.
- Don't change MTX without your rheumatologist. Reclaim does not recommend stopping or reducing MTX based on CBD use.
- Other autoimmune-stack interactions. If you also take a biologic, prednisone, or hydroxychloroquine, see the per-medication pages for each.
Methotrexate brand names
| Brand name | Generic | Form |
|---|---|---|
| Rheumatrex | Methotrexate | Oral tablet |
| Trexall | Methotrexate | Oral tablet |
| Otrexup | Methotrexate | Subcutaneous auto-injector |
| Rasuvo | Methotrexate | Subcutaneous injection |
Subcutaneous MTX (Otrexup, Rasuvo) bypasses first-pass metabolism somewhat, which slightly changes the metabolic profile. This page applies to both routes; the CYP3A4 + UGT involvement remains.
Frequently asked questions
Can I take CBD if I'm on methotrexate?
Yes, with your rheumatologist in the loop. The interaction is real, CBD inhibits CYP3A4 which partially clears MTX, so MTX levels can rise. Bansal 2023 confirmed this mechanism clinically. The practical implication is that your existing monitoring (CBC, liver function) becomes more important, not that you can't use CBD. Tell your rheumatologist and let them adjust monitoring accordingly.
Is the topical roll-on or transdermal patch safer with methotrexate than the oil?
Possibly — at least from a CYP-exposure perspective. Oral CBD has the highest first-pass through the liver and therefore the largest CYP impact. Topical CBD has minimal systemic absorption. Transdermal patches deliver CBD systemically but at lower peak concentrations than oral. If your rheumatologist supports a CBD trial, the lower-systemic-exposure formats reduce the CYP-pathway concern.
What about CBD and MTX side effects? Can it help with the nausea?
No clinical trial exists for this specifically, but CBD has well-documented antiemetic mechanisms and many people report GI relief. The honest answer: it may help, and it's worth discussing. But if MTX side effects are severe, the first conversation is with your rheumatologist, dose, timing, route, and folate are levers they control. CBD is a parallel track, not a substitute for that conversation.
I take MTX once a week. Does the timing of CBD relative to MTX matter?
Possibly. CBD's CYP inhibition outlasts its plasma half-life — the enzyme inhibition can persist for hours. If you take MTX once weekly, the CYP3A4 pathway is most relevant on the day of MTX administration; daily CBD use means CYP3A4 is partially inhibited every day. Whether to time CBD differently around MTX administration is a question for your rheumatologist.
Will my rheumatologist know about this?
Maybe, maybe not. A 2018 Arthritis Foundation survey found 58% of patients who told their doctor about CBD use did not get the safety, dosing, or interaction information they were looking for. Many rheumatologists are under-informed because CBD-Rx interaction research is recent. Bring this page to your appointment. The CYP3A4 + UGT framing helps the conversation move from "I'd avoid it" to "let's discuss your monitoring and timing."
References
- Bansal S et al. (2023). Cannabidiol effects on the pharmacokinetics of substrates of cytochrome P450 enzymes. PMID 37313955
- Stöllberger C, Finsterer J. (2023). Interactions between cannabidiol and commonly used prescription drugs. PMID 37541924
- Yamaori S et al. (2011). Cannabidiol is a potent inhibitor of cytochrome P450 enzymes. PMID 21356216
- Cuñetti L et al. (2024). Cannabidiol elevated cyclosporine and mycophenolate levels in a kidney transplant patient. PMID 38212169
- Nachnani R et al. (2024). Cannabidiol-prescription drug interactions: a systematic review. PMID 38868665
Related reading
Some related pages are still being written.